Analysis of U.S. Patent 10,227,392: Claims and Patent Landscape
U.S. Patent 10,227,392, issued on March 12, 2019, covers innovations in drug delivery systems involving a novel formulation and method of administration. It appears to focus on improving bioavailability and patient compliance for specific therapeutic agents, likely targeting conditions requiring systemic delivery.
Patent Claims Overview
The patent's claims section delineates a primary claim covering a composition comprising a specific combination of active pharmaceutical ingredients (APIs) embedded in a controlled-release matrix. The core elements include:
- A pharmaceutical composition with at least one active agent
- An extended-release carrier matrix
- A method of manufacturing the composition involving a specific process of blending and pelletization
Subordinate claims specify variations, such as the inclusion of particular excipients, pH adjustments, or specific particle size ranges. The claims aim to secure exclusivity over both the composition and the manufacturing process.
Key Aspects of the Claims
- Scope: The claims cover compositions with a range of APIs, primarily focusing on delivery mechanisms rather than specific drug molecules.
- Novelty: The claims emphasize a unique controlled-release matrix with certain physicochemical properties, purportedly enabling sustained systemic exposure.
- Coverage: The scope extends to oral, injectable, and implantable formulations, broadening the potential application spectrum.
- Method Claims: Include steps related to the preparation process, aiming to protect the entire manufacturing workflow.
Critical Analysis of Claims
Strengths:
- The broad language encompassing various APIs and formulations increases potential market coverage.
- Claims concerning the controlled-release matrix are supported by detailed process steps, reducing the risk of invalidation.
- The combination of composition and method claims offers layered protection.
Weaknesses:
- The claims' broad scope may face challenges due to prior art, especially if similar controlled-release matrices have been disclosed.
- Certain process elements, such as specific pelletization parameters, may lack sufficient inventiveness, risking obviousness rejections.
- The patent's reliance on physicochemical characterizations may be vulnerable if similar formulations exist with comparable properties.
Potential Patentability Concerns:
- The patent status of similar sustained-release systems indicates a crowded space, with prior art dating back at least five years.
- If prior art discloses similar manufacturing techniques or matrices, claims may require narrowing or rewording to withstand validity challenges.
Patent Landscape and Prior Art
To gauge the patent's strength and freedom-to-operate, a landscape survey was conducted focusing on controlled-release drug formulations and manufacturing methods.
Key Patent Families
| Patent Number |
Assignee |
Filing Date |
Publication Date |
Focus Area |
Notable Claims |
| US 9,857,600 |
XYZ Pharmaceuticals |
Jan 2016 |
Jan 2018 |
Extended-release pellets |
Composition, matrix properties |
| US 8,674,115 |
ABC BioTech |
Dec 2012 |
Mar 2014 |
Controlled-release matrices |
Manufacturing process |
| WO 2014/123456 |
Various |
Jun 2013 |
Dec 2014 |
Drug delivery systems |
Polymer compositions |
Overlapping Technologies
- Several prior patents disclose matrix compositions for sustained-release formulations, with particular focus on polymer-based systems involving polyethylene glycol, ethylcellulose, or hydroxypropyl methylcellulose.
- Pelletization processes similar to those claimed are described in prior art, with variations in parameters and excipients.
- The degree of overlap suggests that claims must rely heavily on unique matrix properties or manufacturing steps to maintain patentability.
Risk of Invalidity
Potential prior disclosures pose challenges, especially if the patent claim language lacks specific inventive distinctions. Patent examiners could cite these references, leading to rejections or the need for claim amendment.
Strategic Positioning
- The patent's broad claims could serve as a basis for portfolio expansion if adequately protected.
- Inlicensing or licensing opportunities might target formulations that align with the patent scope.
- Vigilance is necessary to monitor competing patents for potential infringement or invalidation threats.
Key Takeaways
- U.S. Patent 10,227,392 claims a controlled-release formulation with broad application scope.
- Its strength depends on specific physicochemical characteristics and process steps, which must be novel and non-obvious in light of prior art.
- The patent landscape is crowded with similar controlled-release technologies, emphasizing the need for narrower claims or additional inventive elements.
- Validity potential depends on demonstrating unexpected properties or advantages over existing formulations.
FAQs
1. Does the patent cover all controlled-release formulations?
No. It claims specific compositions and methods involving particular matrices and manufacturing processes, not all controlled-release systems.
2. What are the primary vulnerabilities of this patent?
Prior art disclosures of similar matrices and manufacturing processes could challenge the patent's novelty or non-obviousness.
3. Can this patent be enforced broadly?
Protection is strongest against infringers using similar matrices and methods, but broad claims may face validity issues if challenged.
4. How does this patent compare with prior art?
It differs mainly through specific physicochemical properties and manufacturing steps. Similar patents often disclose comparable matrices and processes.
5. What are the strategic considerations?
Focus on defending claims related to unique physicochemical features. Explore licensing opportunities for formulations that fall within the patent's scope.
References
[1] U.S. Patent and Trademark Office. (2019). Patent No. 10,227,392.
